Ahmed Magdy Rabea/LinkedIn
May 21, 2025, 12:50
Ahmed Magdy Rabea: Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients with Relapsed/Refractory Multiple Myeloma
Ahmed Magdy Rabea, Head of Medical Oncology Department at Shifa Hospital, shared a post on LinkedIn:
“I’m proud to share my recent contribution to a newly published article in Clinical Lymphoma, Myeloma & Leukemia (May 19, 2025):
“Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients with Relapsed/Refractory Multiple Myeloma: Recommendations from the Middle East and North Africa Expert Panel.”
This work provides practical insights and expert recommendations tailored to the management of belantamab mafodotin in relapsed/refractory multiple myeloma, specifically from the perspective of clinicians across the MENA region.
It’s been a privilege to collaborate with such a distinguished group of colleagues and experts in the field. Grateful for the opportunity to contribute to this important guidance.”
More posts featuring Ahmed Magdy Rabea.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 21, 2025, 12:38
May 21, 2025, 12:32
May 21, 2025, 12:14
May 21, 2025, 12:07
May 21, 2025, 11:32
May 21, 2025, 09:58